We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2926
KALA BIO
KALA
$14.5M
| $175K | ﹤0.01% |
27
+1
| +4% | +$8.63K |
|
|
FTH
2927
Faeth Therapeutics
FTH
$629M
| $174K | ﹤0.01% |
+829
| New | +$151K |
|
|
ICAD
2928
DELISTED
iCAD Inc
ICAD
| $171K | ﹤0.01% |
15,903
+1,025
| +7% | +$13.3K |
|
|
TIG
2929
DELISTED
Trean Insurance Group, Inc. Common Stock
TIG
| $169K | ﹤0.01% |
16,359
+609
| +4% | +$7.24K |
|
|
NBEV
2930
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
| $169K | ﹤0.01% |
121,510
+4,033
| +3% | +$7.34K |
|
2931
Ouster
OUST
$2.92B
| $168K | ﹤0.01% |
2,301
+77
| +3% | +$7.1K |
|
|
QTNT
2932
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $167K | ﹤0.01% |
1,782
+66
| +4% | +$8.24K |
|
|
EVLO
2933
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $166K | ﹤0.01% |
1,182
+51
| +5% | +$10.1K |
|
2934
Eterna Therapeutics
ERNA
$4.91M
| $165K | ﹤0.01% |
2
| – | – |
|
2935
Adicet Bio
ACET
$74.7M
| $163K | ﹤0.01% |
1,301
+35
| +3% | +$4.34K |
|
2936
Verrica Pharmaceuticals
VRCA
$87.3M
| $162K | ﹤0.01% |
1,298
+14
| +1% | +$1.57K |
|
2937
Torrid Holdings
CURV
$260M
| $160K | ﹤0.01% |
+10,377
| New | +$246K |
|
2938
Finance of America Companies
FOA
$198M
| $159K | ﹤0.01% |
3,222
+165
| +5% | +$9.8K |
|
2939
Design Therapeutics
DSGN
$876M
| $156K | ﹤0.01% |
+10,589
| New | +$176K |
|
|
INZY
2940
DELISTED
Inozyme Pharma
INZY
| $156K | ﹤0.01% |
13,462
+675
| +5% | +$10.5K |
|
|
NEXI
2941
DELISTED
NexImmune, Inc. Common Stock
NEXI
| $156K | ﹤0.01% |
+413
| New | +$139K |
|
2942
LiveOne
LVO
$58.2M
| $155K | ﹤0.01% |
5,181
+248
| +5% | +$8.58K |
|
|
EEX
2943
DELISTED
Emerald Holding
EEX
| $152K | ﹤0.01% |
35,016
-1,219
| -3% | -$5.46K |
|
2944
InfuSystem Holdings
INFU
$249M
| $150K | ﹤0.01% |
11,530
+825
| +8% | +$13.5K |
|
|
STR
2945
DELISTED
Sitio Royalties
STR
| $150K | ﹤0.01% |
7,965
-114
| -1% | -$2.13K |
|
2946
ASE Group
ASX
$82.2B
| $149K | ﹤0.01% |
+18,978
| New | +$165K |
|
2947
Duluth Holdings
DLTH
$159M
| $148K | ﹤0.01% |
10,822
+466
| +4% | +$7.43K |
|
2948
Retractable Technologies
RVP
$20.1M
| $148K | ﹤0.01% |
13,462
+777
| +6% | +$9.09K |
|
2949
Vitamin Cottage Natural Grocers
NGVC
$654M
| $147K | ﹤0.01% |
13,120
+516
| +4% | +$5.74K |
|
2950
Tilray
TLRY
$622M
| $145K | ﹤0.01% |
1,284
| – | – |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.